Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

2018 Corlanor (ivabradine; Servier/Amgen/Ono Pharmaceutical) Drug Analysis - ResearchAndMarkets.com

Research and Markets
Posted on: 20 Feb 18

The "Drug analysis: Corlanor" drug pipelines has been added to ResearchAndMarkets.com's offering.

Corlanor (ivabradine; Servier/Amgen/Ono Pharmaceutical) blocks f-channels and inhibits the f-current, a modulator of the heart's pacemaker activity. Heart rate (HR) depends on the speed of diastolic depolarization of myocytes from the sinus node. By binding to the f-channels of sinoatrial cells, Corlanor blocks the inward flow of sodium and potassium.

This prolongs the myocytes' depolarization phase, and slows HR. A lower HR decreases cardiac oxygen consumption, and prolonged diastolic times increase myocardial perfusion. Corlanor's improvements in overall oxygen levels help to reduce cardiovascular risk. The drug's pure HR-lowering properties prevent it from affecting contractility, or intracardiac conduction.

Key Topics Covered:

Product Profiles

Corlanor: Chronic heart failure (CHF)

List of Figures

Figure 1: Corlanor for chronic heart failure - SWOT analysis

Figure 2: Drug assessment summary of Corlanor for chronic heart failure

Figure 3: Drug assessment summary of Corlanor for chronic heart failure

Figure 4: Corlanor sales for chronic heart failure across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

Table 1: Corlanor drug profile

Table 2: Corlanor pivotal phase III trial data in chronic heart failure

Table 3: Corlanor Phase II trial data in chronic heart failure

Table 4: Corlanor sales for chronic heart failure across the US, Japan, and five major EU markets, by country ($m), 2017-26

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/jrc7wz/2018_corlanor?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180220006287/en/

Business Wire
www.businesswire.com

Last updated on: 20/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.